News | Pharmaceuticals | March 22, 2022

Fresenius Kabi Receives FDA 510(k) Clearance for Wireless Agilia Connect Infusion System with Vigilant Software Suite-Vigilant Master Med Technology

The wirelessly connected infusion pump system for hospitals and clinics enables centralized distribution of custom drug libraries and warehousing of infusion data for reporting and analysis

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, has announced it has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for its wireless Agilia Connect Infusion System which includes the Agilia Volumetric Pump and the Agilia Syringe Pump with Vigilant Software Suite-Vigilant Master Med technology.

March 22, 2022 – Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, has announced it has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for its wireless Agilia Connect Infusion System which includes the Agilia Volumetric Pump and the Agilia Syringe Pump with Vigilant Software Suite-Vigilant Master Med technology. The Agilia Connect volumetric pump and syringe pump are the first to be cleared by following TIR101 standards, which were developed by the Association for the Advancement of Medical Instrumentation (AAMI) in 2021.

The wireless Agilia Connect Infusion System has been globally available since 2016 and has more than 126,000 customer installations. The Agilia Connect Infusion System builds on the company’s first generation Agilia Infusion System, available in more than 130 countries with more than 1.2 million customer installations, to provide wireless connectivity through the Vigilant Software Suite. This software suite includes Vigilant Master Med drug library software, Vigilant Insight infusion analytics software and Agilia Partner calibration and maintenance software. The product offering enables the centralized distribution of drug libraries, warehousing of infusion data for reporting and analysis and wireless maintenance and calibration of devices.

Both patients and caregivers benefit from smarter devices that make health care safer and easier,” said John Ducker, president and CEO of Fresenius Kabi USA. “As a company with more than 35 years of global infusion technology expertise we look forward to establishing Fresenius Kabi as the partner of choice for infusion therapy in the U.S.”

Focused on patient safety and designed to drive best practices, Agilia features customized Master Drug Libraries based on each hospital or clinic’s approved medication protocols. These drug libraries can be distributed wirelessly to an entire fleet of Agilia Connect Pumps, safely and securely. With the Vigilant Insight Continuous Quality Improvement software, infusion data can be configured on demand into reports. This enables providers to conduct independent performance analyses across multiple health care facilities to help reach their infusion practice and patient safety goals.

For more information: www.fresenius-kabi.com/us

Related Content

News | Pharmaceuticals

May 24, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

Home May 24, 2022
Home
News | Pharmaceuticals

May 24, 2022 — The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has ...

Home May 24, 2022
Home
News | Pharmaceuticals

May 17, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

Home May 17, 2022
Home
News | Pharmaceuticals

May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) ...

Home May 13, 2022
Home
News | Pharmaceuticals

April 29, 2022 — Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Camzyos ...

Home April 29, 2022
Home
News | Pharmaceuticals
March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions ...
Home March 31, 2022
Home
News | Pharmaceuticals

January 5, 2022 — The Feinstein Institutes for Medical Research, the science arm of Northwell Health, recently received ...

Home January 05, 2022
Home
News | Pharmaceuticals

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has cleared Novartis' inclisiran (Leqvio), the first small ...

Home January 04, 2022
Home
News | Pharmaceuticals

December 16, 2021 – Spanish pharmaceutical company Ferrer and the Spanish National Center for Cardiovascular Research ...

Home December 16, 2021
Home
Videos | Pharmaceuticals

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at ...

Home November 22, 2021
Home
Subscribe Now